Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
about
Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1Molecular mechanisms of insulin resistance in chronic hepatitis CTNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line Caco-2Immunoproteomic to identify antigens in the intestinal mucosa of Crohn's disease patients.Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.The vascular endothelium in diabetes--a therapeutic target?Unresolved issues in biologic therapy for rheumatoid arthritis.Epidemiology, risk factors and management of cardiovascular diseases in IBD.Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease.Tumor Necrosis Factor Alpha Inhibitor-Induced Acute Pancreatitis.Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.Endocrine and metabolic manifestations in inflammatory bowel diseaseAn overview of lipid abnormalities in patients with inflammatory bowel diseaseLipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis.Association Between Adipokines Levels with Inflammatory Bowel Disease (IBD): Systematic Reviews.Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease.Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease.
P2860
Q26752511-4FDEEE83-6209-4A70-928B-4BEF4BE9EE2EQ27489665-626EBEB6-8566-4B06-B0FF-644897E8EBFEQ34559884-DA59C192-C873-43DE-959B-8F7A35B672DDQ35072537-87EC6211-FFFA-442C-9BCC-DB68415CD520Q35526652-CAA883A5-370F-468B-AB6F-97BDB4F7A881Q36673550-E9C2D0BA-B200-4018-A551-10CDAF4E3DE7Q37851001-D8FAC53A-400C-468A-AF52-6FAFE0862C5CQ38275040-84D263F8-178C-4357-97E0-DA41FB74BA47Q40378427-9178DC12-9B94-4034-86ED-4E94BBD6F601Q41563909-409CD597-3355-4094-BBC8-B4982B14047EQ42378152-9D92DE7A-44A9-47FA-B07F-32400BE7E5A0Q42406756-6829F99F-39B5-49EB-9999-3AEED77F4112Q42406811-F2B7D52D-F734-437E-BD03-DC0F3ECB010CQ42472908-477B3648-B553-41EF-9D38-A7EE5F59C003Q47203093-F653D76A-50C1-4319-9D29-8DD2944EF367Q47584731-64F23013-DE2D-45C1-BBA3-01834EC6C95FQ47990338-DAC8B66F-876D-489E-8D95-0D62E41B8E12Q51244473-57BE538D-5E35-4D09-A0BB-758DD1499584
P2860
Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Effects of tumor necrosis fact ...... th inflammatory bowel disease.
@en
Effects of tumor necrosis fact ...... th inflammatory bowel disease.
@nl
type
label
Effects of tumor necrosis fact ...... th inflammatory bowel disease.
@en
Effects of tumor necrosis fact ...... th inflammatory bowel disease.
@nl
prefLabel
Effects of tumor necrosis fact ...... th inflammatory bowel disease.
@en
Effects of tumor necrosis fact ...... th inflammatory bowel disease.
@nl
P2093
P50
P1476
Effects of tumor necrosis fact ...... ith inflammatory bowel disease
@en
P2093
Elias A Kouroumalis
Ioannis Chalkiadakis
Niki Malliaraki
Nikolaos Karkavitsas
Pantelis Oustamanolakis
P304
P356
10.1097/MEG.0B013E328325D42B
P577
2009-03-01T00:00:00Z